🔗 Share this article Recent Antimicrobials Hailed as a 'Pivotal Moment' in Addressing Drug-Resistant Gonorrhoea The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to health experts. An International Health Concern Gonorrhoea infections are increasing worldwide, with estimates suggesting over 82 million instances each year. Particularly high rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to those in 2014. “The authorization of novel therapies for gonorrhoea is an important and timely development in the context of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options presently on offer.” Health officials are deeply concerned about the rise in treatment-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024. A Pair of Novel Therapies Receive Approval One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help delay the development of resistance. Gepotidacin, originating from the pharmaceutical company GSK, was also approved in the same week. This treatment, which is also used to treat UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria. A Novel Partnership Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company its industry partner to develop it. “This milestone marks a huge turning point in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.” Clinical Trial Data and Worldwide Availability Based on data detailed in a prominent scientific publication, the new drug cured over nine in ten of uncomplicated infections. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The research involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US. As part of the agreement of its unique model, the non-profit has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries. Medical professionals on the front lines have voiced optimism. Having a single-dose, oral treatment of this kind is hailed as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea globally.